WT1 and acute myeloid leukemia: The findings reported by Anguille et al.334 demonstrated that this vaccination approach effectively elicits robust T-cell immune responses in AML patients at high risk of relapse, thereby establishing both the safety and potential utility of autologous WT1 mRNA-electroporated DC vaccine following chemotherapy.